Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 153 publications
Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides.
Journal: JAMA dermatology
Published: June 17, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Journal: Blood cancer journal
Published: January 27, 2026
Clinicopathologic features of systemic ALK-negative anaplastic large cell lymphoma with TP53 deletion.
Journal: American journal of clinical pathology
Published: January 26, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Journal: Blood cancer discovery
Published: January 20, 2026
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.
Journal: American journal of hematology
Published: September 03, 2025
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.
Journal: Blood advances
Published: July 14, 2025
Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.
Journal: Blood advances
Published: July 14, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.
Journal: Nature medicine
Published: June 26, 2025
Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy.
Journal: Therapeutic advances in medical oncology
Published: May 17, 2025
Last Updated: 09/26/2026